[EMAIL PROTECTED] writes:
NEW YORK, May 3 (Reuters) - Government scientists are excited about
progress with tests on two cancer drugs that are eradicating any type of
cancer in mice, the New York Times reported on Sunday.
["Government scientists," which Mac naturally confuses with "leaders in this
field," seem to have been able to maintain their excitement for a very long
time over this creeping breakthrough.
A careful reader might have noted the following item at the end of the
story:]
Several companies are also working to develop the drugs, and both have been
reported about extensively...
[One of those companies seems further along in submitting a New Drug
Application - specifically for lung cancer. Unfortunately for them they do
not have the flaks that EntreMed (and Bristol Meyers) have.]
[Making old news new - note the dates:]
Endostatin, Newly Discovered Angiogenic Inhibitor Licensed
ROCKVILLE, Md.�Dec. 5, 1996 -- EntreMed, Inc., announced today that it
licensed the worldwide rights to the newly discovered angiogenesis
inhibitor, Endostatin(TM), from Children's Hospital, a teaching affiliate of
the Harvard Medical School in Boston, MA. EntreMed acquired these rights
through an exclusive sponsored research agreement with Children's Hospital
that supports the angiogenesis research of Dr. Judah Folkman and Resources
his team of scientists.
{-]
Antiangiogenic drugs have the potential to treat cancer as well as a variety of
other angiogenic diseases such as blindness and arthritis...
[Too bad they couldn't be working a bit harder on those illnesses with the
new miracle drug but I guess one thing at a time.]
At a recent Massachusetts Institute of Technology cancer research conference
sponsored by the Whitehead Institute for Biomedical Research, Dr. Folkman
announced that the combination of Endostatin(TM) and Angiostatin(TM), when
used in preclinical studies to treat solid tumors for which there is no
effective chemotherapy, prevented the reoccurrence of the tumors even months
after cessation of the combined treatment. These findings from Drs. Michael
O'Reilly and Judah Folkman, along with their research team, were recently
cited in The Boston Globe (October 23, 1996), The Economist (November 16,
1996), and U.S. News & World Report (December 9, 1996).
[Think maybe those other clowns were not colorful enough in their blurbs?]
[-]
EntreMed Chairman, President and Chief Executive Officer Dr. John W.
Holaday: "...we are extending our significant efforts to accelerate the
availability of angiogenesis products for the treatment of cancer,
blindness, and other diseases that depend on new blood vessel growth."
[Damn. Arthritis just became "other diseases." But at least there is
better hope for the vision challenged.]
Best, Terry
"Lawyer - one trained to circumvent the law" - The Devil's Dictionary
Subscribe/Unsubscribe, email: [EMAIL PROTECTED]
In the body of the message enter: subscribe/unsubscribe law-issues
